- Status:
- Red
- Decision Date:
- None
Comments
RED: NICE TA742 - Selpercatinib for treating advanced thyroid cancer with RET alterations. (Decision date - December 2021)
RED: NICE TA760 - Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. (Decision date - February 2022)
RED: NICE TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small-cell
lung cancer. (Decision date - August 2023)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again
